A comparative analysis of risk management strategies in European union and united states pharmaceutical regulation

Health, Risk and Society

Volumn 13, Issue 5, 2011, Pages 413-431

  Davis, Courtney ^a   Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Flip flop; Regulatory regimes; Risk; Risk colonisation pharmaceuticals; Risk management

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; COMPARATIVE STUDY; DRUG CONTROL; DRUG INDUSTRY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; PATIENT MONITORING; RISK MANAGEMENT; UNITED STATES;

EID: 79961153030     PISSN: 13698575     EISSN: 14698331     Source Type: Journal    
DOI: 10.1080/13698575.2011.596191     Document Type: Article

References (72)

1. Abraham, J., 1995. Science, politics and the pharmaceutical industry. London/New York:UCL/St Martins Press.
2. Abraham, J. and Davis, C., 2005a. Risking public safety: Experts, the medical profession and 'acceptable' drug injury. Health, Risk & Society, 7, 379-395.
3. Abraham, J. and Davis, C., 2005b. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992). Social Science and Medicine, 61, 881-892.
4. Abraham, J. and Davis, C., 2006. Testing times: The emergence of the practolol disaster and its challenge to British drug regulation in the modern period. Social History of Medicine, 19, 127-147.
5. Abraham, J. and Davis, C., 2009. Drug evaluation and the permissive principle: Continuities and contradictions between standards and practices in antidepressant regulation. Social Studies of Science, 39, 569-598.
6. Abraham, J. and Davis, C., 2010. Discovery and management of adverse drug reactions: The nomifensine hypersensitivity syndrome, 1977-86. Social History of Medicine, 23, 153-173.
7. Abraham, J. and Lewis, G., 2000. Regulating medicines in Europe: Competition, expertise and public health. London: Routledge.
8. Abraham, J. and Millstone, E., 1989. Food additive controls: Some international comparisons. Food Policy, 14, 43-57.
9. Abraham, J. and Reed, T., 2001. Trading risks for markets: The international harmonization of pharmaceuticals regulation. Health, Risk & Society, 3, 113-128.
10. Alivisatos, R., 1997. FDA Medical Officer's Review of NDA 20-759 (Trovan), 20 July.
11. Alivisatos, R., 1998. FDA Medical Officer's Review. Post-Marketing Adverse Events NDA 20-760 (Trovan), 31 August.
12. Andersson, F., 1992. The drug lag issue: The debate seen from an international perspective. International Journal of Health Services, 22, 53-72.
13. Anon, 2001a. More restrictions for Orlaam. Scrip, 3 January, p. 14.
14. Anon, 2001b. Orlaam suspended in EC. Scrip, 25 April, p. 12.
15. Anon, 2003. Roxane to discontinue Orlaam in the US. Scrip, 17 September, p. 11.
16. Anon, 2004. Tasmar EU suspension to be lifted, but with closer monitoring. Scrip, 30 April, p. 12.
17. Bevan, G., 2008. Changing paradigms of governance and regulation of quality of healthcare in England. Health, Risk & Society, 10, 85-101.
18. Blanchemanche, S., Marette, S., Roosen, J., and Verger, P., 2010. 'Do not eat fish more than twice a week': Rational choice, regulation and risk communication. Health, Risk & Society, 12, 271-292.
19. Brickman, R., Jasanoff, S., and Ilgen, T., 1985. Controlling chemicals: The politics of regulation in Europe and the US. Ithaca, NY: Cornell University Press.
20. Chapman, A., 2006. Regulating chemicals: From risks to riskiness. Risk Analysis, 26, 603-616.
21. Cox, L.A., 2007. Does concern-driven risk management provide a viable alternative to QRA. Risk Analysis, 27, 27-43.
22. Currie, G., Humphreys, M., Waring, J., and Rowley, E., 2009. Narratives of professional regulation and patient safety: Medical devices in anaesthetics. Health, Risk & Society, 11, 117-135.
23. Daemmrich, A., 2004. Pharmacopolitics: Drug regulation in the United States and Germany. Chapel Hill/London: University of North Carolina Press.
24. Daemmrich, A. and Krucken, G., 2000. Risk versus risk: Decision-making dilemmas in the United States and Germany. Science as Culture, 9, 505-534.
25. Davis, C. and Abraham, J., 2010a. Rethinking innovation accounting in pharmaceutical regulation. Science, Technology & Human Values, 35, 1-22.
26. Davis, C. and Abraham, J., 2010b. Desperately seeking cancer drugs: Explaining the emergence and outcomes of accelerated pharmaceutical regulation. Sociology of Health & Illness, 32, 1-22.
27. Demortain, D., 2008. From drug crises to regulatory change. Health, Risk & Society, 10, 37-51.
28. Earle, T.C., 2010. Trust in risk management. Risk Analysis, 30, 541-574.
29. EMEA., 1997. European Public Assessment Report (Tasmar).
30. EMEA., 1998. Recommendation for the Suspension of the Marketing Authorisation for Tasmar (tolcapone) - EU/1/97/044/001-006, CPMP/2457/98, 17 November.
31. EMEA., 1999a. Public Statement on Trovan (Trovafloxacin): Serious, Severe and Unpredictable Liver Injuries, EMEA/15770/99, 25 May.
32. EMEA., 1999b. Public Statement on Trovan (Trovafloxacin): Recommendation to Suspend the Marketing Authorisation in the European Union, EMEA/18046/99, 15 June.
33. EMEA., 1999c. Public Statement on Levacetylmethadol (Orlaam) - for Life-Threatening Cardiac Rhythm Disorders, EMEA/38436/99, 15 December.
34. EMEA., 2000. Public Statement on Levacetylmethadol (Orlaam) - Life-Threatening Ventricular Rhythm Disorders, EMEA/38918/00, 19 December.
35. EMEA., 2001. European Public Assessment Report, Revision 4 (Orlaam): CPMP Scientific Discussion, CPMP/169/97.
36. FDA., 1993. Approved Label, NDA 20-315 (Orlaam).
37. FDA., 1994. FDA Consumer, November.
38. FDA., 1998. FDA Talk Paper.
39. FDA., 1999a. Managing the risks from medical product use: Creating a risk management framework. Washington, DC: Department of Health and Human Services.
40. FDA., 1999b. Public Health Advisory - Trovan, 9 June.
41. FDA., 2000. CDER-PhRMA-AASLC Conference 2000, Clinical White Paper, November 2000.
42. Gillespie, B., Eva, P., and Johnston, R., 1979. Carcinogenic risk assessment in the US and Great Britain: The case of aldrin/dieldrin. Social Studies of Science, 9, 265-301.
43. Graham, D.J., Drinkard, C.R., Shatin, D., Tsong, Y., and Burgess, M.J., 2001. Liver enzyme monitoring in patients treated with troglitazone. Journal of the American Medical Association, 286, 831-834.
44. Halffman, W., 2005. Science-policy boundaries: National styles? Science and Public Policy, 32, 457-467.
45. Hammitt, J.K., Wiener, J.B., Swedlow, B., Kall, D., and Zhou, Z., 2005. Precautionary regulation in Europe and the United States: A quantitative comparison. Risk Analysis, 25, 1215-1228.
46. Hancher, L., 1989. Regulating for competition: Government, law, and the pharmaceutical industry in the UK and France. Thesis (PhD). University of Amsterdam.
47. Hood, C. and Rothstein, H., 2001. Risk regulation under pressure: Problem solving or blame shifting? Administration & society, 33, 21-53.
48. Hood, C., Rothstein, H., and Baldwin, R., 2001. The government of risk: Understanding risk regulation regimes. Oxford: Oxford University Press.
49. Jasanoff, S., 1986. Risk management and political culture. New York: Russell Sage Foundation.
50. Jasanoff, S., 2005. Designs on nature: Science and democracy in Europe and the US. Princeton/Oxford: Princeton University Press.
51. Katz, R., 1997. FDA Supervisory Review of NDA 20-697, Tasmar, 6 April.
52. Keijsers, L., Bossong, M.G., and Waarlo, A.J., 2008. Participatory evaluation of a Dutch warning campaign for substance-users. Health, Risk & Society, 10, 283-295.
53. Kelman, S., 1981. Regulating Sweden, regulating America: A comparative study of occupational health and safety policy. Cambridge, MA: MIT Press.
54. La Revue Prescrire., 1999. A review of new drugs. Prescrire International, 8, 5-20.
55. Leitch, M., 2010. ISO 31000:2009 - the new international standard on risk management. Risk Analysis, 30, 887-892.
56. Levidow, L. and Carr, S., 2000. Normalizing novelty: Regulating biotechnological risk at the EPA. Risk, 11, 9-34.
57. Lloyd-Bostock, S.M. and Hutter, B.M., 2008. Reforming regulation of the medical profession:The risk of risk-based approaches. Health, Risk & Society, 10, 69-83.
58. Macrae, C., 2008. Learning from patient safety incidents: Creating participative risk regulation in healthcare. Health, Risk & Society, 10, 53-67.
59. Osimani, B., 2010. Pharmaceutical risk communication: Sources of uncertainty and legal tools of uncertainty management. Health, Risk & Society, 12, 453-469.
60. Purdy, G., 2010. ISO 31000:2009 - setting a new standard for risk management. Risk Analysis, 30, 881-886.
61. Roche Hexagon., 1998. Product Label for Tasmar.
62. Rothstein, H., 2006. The institutional origins of risk. Health, Risk & Society, 8, 215-221.
63. Smalley, W., Shatin, D., Wysowski, D.K., Gurwitz, J., et al., 2000. Contraindicated use of cisapride: Impact of FDA regulatory action. Journal of the American Medical Association, 284, 3036-3039.
64. Taylor-Gooby, P. and Zinn, J.O., 2006. Current directions in risk research. Risk Analysis, 26, 397-411.
65. Temin, P., 1980. Taking your medicine: Drug regulation in the United States. Cambridge, MA: MIT Press.
66. USNRC, 1983. Risk assessment in the Federal Government: Managing the process. Washington DC: National Research Council.
67. Van Zwanenberg, P. and Millstone, E., 2005. BSE: Risk, science, and governance. Oxford: Oxford University Press.
68. Vogel, D., 1986. National styles of regulation: Environmental policy in Great Britain and the United States. Ithaca, NY: Cornell University Press.
69. Vogel, D., 2003. The hare and the tortoise revisited: The new politics of consumer and environmental regulation in Europe. British Journal of Political Science, 33, 557-580.
70. Waller, P. and Evans, S., 2002. A model for the future conduct of pharmacovigilance. Pharmacoepidemiology and Drug Safety, 10, 773-786.
71. Welsh, R. and Ervin, D.E., 2006. Precaution as an approach to technology development: The case of transgenic crops. Science, Technology & Human Values, 31, 153-172.
72. Wiktorowicz, M.E., 2003. Emergent patterns in the regulation of pharmaceuticals: Institutions and interests in the US, Canada, Britain and France. Journal of Health, Politics, Policy and Law, 28, 615-658.